{
  "doc": {
    "accession": "0001193125-23-194715",
    "filingType": "8-K",
    "filedDate": "2023-07-26",
    "companyName": "Alnylam Pharmaceuticals, Inc.",
    "cik": "0001178670"
  },
  "event": {
    "kind": "Partnership",
    "secItem": "Item 1.01",
    "headline": "Entry into a Material Definitive Agreement.",
    "summary": "Alnylam Pharmaceuticals, Inc. entered into a Collaboration and License Agreement with F. Roche Ltd. and Genentech, Inc. for the joint development of pharmaceutical products containing zilebesiran.",
    "effectiveDate": "2023-07-21"
  },
  "partnership": {
    "partnerA": "Alnylam Pharmaceuticals, Inc.",
    "partnerB": "F. Roche Ltd.",
    "scope": "joint development of pharmaceutical products containing zilebesiran",
    "territory": "worldwide",
    "upfrontPaymentUSD": 310000000,
    "milestonesUSD": 2500000000
  },
  "provenance": {
    "documents": [
      {
        "role": "primary_filing",
        "filename": "d448801d8k.htm",
        "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
        "sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855"
      },
      {
        "role": "press_release",
        "filename": "ex99-1.htm",
        "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801dex991.htm",
        "sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855"
      }
    ]
  },
  "evidence": [
    {
      "field": "doc.accession",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT"
    },
    {
      "field": "doc.filingType",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "CURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934"
    },
    {
      "field": "doc.filedDate",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Date of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )"
    },
    {
      "field": "doc.companyName",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Alnylam Pharmaceuticals, Inc.\n(Exact name of registrant as specified in its charter)"
    },
    {
      "field": "doc.cik",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "001-36407\n77-0602661"
    },
    {
      "field": "event.kind",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Item 1.01\tEntry into a Material Definitive Agreement."
    },
    {
      "field": "event.secItem",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Item 1.01\tEntry into a Material Definitive Agreement."
    },
    {
      "field": "event.headline",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "Entry into a Material Definitive Agreement."
    },
    {
      "field": "event.summary",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "On July 21, 2023 (the “”), Alnylam Pharmaceuticals, Inc. (the “”), entered into a Collaboration and License Agreement (the “”) with F. Roche Ltd. (“”) and Genentech, Inc."
    },
    {
      "field": "event.effectiveDate",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Date of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )"
    },
    {
      "field": "partnership.partnerA",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0001",
      "snippet": "Alnylam Pharmaceuticals, Inc."
    },
    {
      "field": "partnership.partnerB",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "with F. Roche Ltd. (“”) and Genentech, Inc."
    },
    {
      "field": "partnership.scope",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "strategic collaboration for the joint development of pharmaceutical products containing zilebesiran"
    },
    {
      "field": "partnership.territory",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "Company and Roche established a worldwide, strategic collaboration"
    },
    {
      "field": "partnership.upfrontPaymentUSD",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "Under the Agreement, Roche will make an upfront payment of $310 million to the Company."
    },
    {
      "field": "partnership.milestonesUSD",
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "selector": "chunk:chunk_0002",
      "snippet": "In addition, the Company will be eligible to receive up to $2.5 billion in contingent payments based on the achievement of specified development, regulatory and sales-based milestones."
    }
  ]
}
